Ann: Telix has Filed Registration Statement for Proposed US IPO, page-22

No I'm not making a direct comparison, just stating that Aussie biotechs haven't had the best time listing in the US and using Mesoblast as a recent example. Obviously Telix is far superior in every respect, but that doesn't mean it wouldn't be subject to the same conditions those other biotechs have experienced. Lantheus' share price has been chopped by a third in recent times, who's to know that wouldn't happen to Telix.

Imo Telix is undervalued on the ASX, this market never values companies appropriately unless they think the margins are huge and overheads are low (ProMedicus?) so it's right for CB and Co to go where they will be appreciated. But that comes with elevated risk also, which is why I think they are being cautious with this rollout. I also think Telix will be compared more favourably against Lantheus because it is cheap, but consider that a hunch more than anything else.